Immunization News and Research

RSS

What is the severity of SARS-CoV-2 Omicron BA.4 and BA.5 variant infections in relation to BA.2 infections?

Researchers compared clinical outcomes of COVID-19 cases due to SARS-CoV-2 Omicron BA.2 and Omicron BA.4/BA.5 variants based on the Kaiser Permanente Southern California (KPSC) health records between April 29 and July 2, 2022.

4 Aug 2022

A combined influenza and COVID-19 mRNA vaccine

A combined mRNA vaccine is capable of inducing broad and durable protection against co-infection with SARS-CoV-2 and IAV,

3 Aug 2022

Hybrid immunity retained six months after SARS-CoV-2 exposure

Scientists hypothesize that lower death rates in COVID-19 patients may be due to hybrid immunity, as well as the reduced severity of Omicron infections.

3 Aug 2022

Adults aged ≥50 years boosted with SARS-CoV-2 mRNA vaccines less likely to experience adverse reactions after second booster than during initial booster

A new study monitored the safety of the second booster dose of SARS-CoV-2 messenger ribonucleic acid vaccination among those ≥50 Years.

2 Aug 2022

What is the efficacy of COVID-19 BNT162b2 and mRNA-1273 booster vaccinations?

In a new study, scientists compared the effectiveness of the SARS-CoV-2 BNT162b2 and mRNA-1273 vaccines booster doses in England.

2 Aug 2022

mRNA vaccines induce faster antibody response against infectious diseases

A new study describes that mRNA vaccines induce antigen-specific antibody response within a very short period of time after immunization.

2 Aug 2022

CDC study describes safety profile of second mRNA COVID booster

The CDC investigates the safety profile of a fourth dose of mRNA-based COVID-19 vaccines in people aged 50 years and older.

1 Aug 2022

RINVOQ® (upadacitinib) Approved by European Commission as an Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis

With this approval, RINVOQ® is the first and only Janus Kinase inhibitor approved to treat patients across the spectrum of axial spondyloarthritis (nr-axSpA and ankylosing spondylitis) in the EU.

From AbbVie 29 Jul 2022

SARS-CoV-2 spike subunit 2–targeted vaccine could more effectively combat all human coronaviruses

In a new study, researchers evidenced that the S2 subunit of SARS-CoV-2 spike (S) could be an integral component of a pan-coronavirus vaccine.

29 Jul 2022

The identification and characterization of an anti-SARS-CoV-2 monoclonal antibody with superior breadth and potency

A recent study published in Nature Microbiology identified a monoclonal antibody neutralizing SARS-CoV-2 Omicron variants.

28 Jul 2022

Incorporating a coronavirus antigen into MMR vaccine to produce COVID-19 immunity in kids

New research has advanced COVID-19 vaccine work in several ways: using a modified live attenuated mumps virus for delivery, showing that a more stable coronavirus spike protein stimulates a stronger immune response, and suggesting a dose up the nose has an advantage over a shot.

27 Jul 2022

India, Pakistan tackle backslide in child immunizations

India and other South Asian countries must deal with a dangerous backslide in routine infant vaccinations during 2019—2021 brought on by the COVID-19 pandemic and restrictions imposed to counter its spread, say UNICEF officials.

27 Jul 2022

Temporal changes in CD4 T-lymphocyte dynamics upon immunization against SARS-CoV-2 spike protein

Researchers assessed changes in CD4 T-lymphocyte temporal dynamics by evaluating T-lymphocyte responses to SARS-CoV-2 S using Foxp3-Tocky mice and Nr4a3-Tocky mice.

27 Jul 2022

Nasal spray highly effective against HIV and SARS-CoV-2 in animal models

The intranasal delivery of amph-protein vaccines is a potential approach to elicit a mucosal immune response against many infectious diseases.

26 Jul 2022

CDC: Novavax's COVID-19 vaccine can be used as another primary series option for adults

Today, CDC Director Rochelle P. Walensky, M.D., M.P.H., endorsed the CDC Advisory Committee on Immunization Practices' (ACIP) recommendation that Novavax's COVID-19 vaccine be used as another primary series option for adults ages 18 years and older.

26 Jul 2022

A VSV-based COVID vaccine effective against SARS-CoV-2 variants

A new study discusses the development of recombinant vesicular stomatitis virus COVID-19 vaccines.

25 Jul 2022

SARS-CoV-2 oral vaccine candidate found to induce neutralizing mucosal IgA

A new study reported the outcomes of a clinical trial evaluating the oral vaccine candidate against SARS-CoV-2 developed by Vaxart.

25 Jul 2022

Study explores how vaccine-related fears influence flu shot outcomes

A novel long-term study of how vaccine-related fears influence flu shot outcomes has found that these fears not only reduce vaccination, but also fuel symptoms of dizziness and lightheadedness at the time of the injection.

21 Jul 2022

Neutralizing activity of skin-patch delivered subunit vaccine against SARS-CoV-2 variants

A new study involved an analysis of the serum from a previous study to determine neutralizing activity against new variants.

20 Jul 2022

What is the impact of lower COVID-19 vaccine doses in younger cohorts?

A new study evaluated the impact of the lower SARS-CoV-2 vaccine dosages in younger populations.

18 Jul 2022

Immunization News and Research

What is the severity of SARS-CoV-2 Omicron BA.4 and BA.5 variant infections in relation to BA.2 infections?

A combined influenza and COVID-19 mRNA vaccine

Hybrid immunity retained six months after SARS-CoV-2 exposure

Adults aged ≥50 years boosted with SARS-CoV-2 mRNA vaccines less likely to experience adverse reactions after second booster than during initial booster

What is the efficacy of COVID-19 BNT162b2 and mRNA-1273 booster vaccinations?

mRNA vaccines induce faster antibody response against infectious diseases

CDC study describes safety profile of second mRNA COVID booster

RINVOQ® (upadacitinib) Approved by European Commission as an Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis

SARS-CoV-2 spike subunit 2–targeted vaccine could more effectively combat all human coronaviruses

The identification and characterization of an anti-SARS-CoV-2 monoclonal antibody with superior breadth and potency

Incorporating a coronavirus antigen into MMR vaccine to produce COVID-19 immunity in kids

India, Pakistan tackle backslide in child immunizations

Temporal changes in CD4 T-lymphocyte dynamics upon immunization against SARS-CoV-2 spike protein

Nasal spray highly effective against HIV and SARS-CoV-2 in animal models

CDC: Novavax's COVID-19 vaccine can be used as another primary series option for adults

A VSV-based COVID vaccine effective against SARS-CoV-2 variants

SARS-CoV-2 oral vaccine candidate found to induce neutralizing mucosal IgA

Study explores how vaccine-related fears influence flu shot outcomes

Neutralizing activity of skin-patch delivered subunit vaccine against SARS-CoV-2 variants

What is the impact of lower COVID-19 vaccine doses in younger cohorts?

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News